Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients : The X-COVID-19 Randomized Trial

© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd..

BACKGROUND: It is uncertain whether higher doses of anticoagulants than recommended for thromboprophylaxis are necessary in COVID-19 patients hospitalized in general wards METHODS: This is a multicentre, open-label, randomized trial performed in 9 Italian centres, comparing 40 mg b.i.d. versus 40 mg o.d. enoxaparin in COVID-19 patients, between April 30 2020 and April 25 2021. Primary efficacy outcome was in-hospital incidence of venous thromboembolism (VTE): asymptomatic or symptomatic proximal deep vein thrombosis (DVT) diagnosed by serial compression ultrasonography (CUS), and/or symptomatic pulmonary embolism (PE) diagnosed by computed tomography angiography (CTA). Secondary endpoints included each individual component of the primary efficacy outcome and a composite of death, VTE, mechanical ventilation, stroke, myocardial infarction, admission to ICU. Safety outcomes included major bleeding.

RESULTS: The study was interrupted prematurely due to slow recruitment. We included 183 (96%) of the 189 enrolled patients in the primary analysis (91 in b.i.d., 92 in o.d.). Primary efficacy outcome occurred in 6 patients (6.5%, 0 DVT, 6 PE) in the o.d. group and 0 in the b.id. group (ARR 6.5, 95% CI: 1.5-11.6). The absence of concomitant DVT and imaging characteristics suggests that most pulmonary artery occlusions were actually caused by local thrombi rather than PE. Statistically nonsignificant differences in secondary and safety endpoints were observed, with two major bleeding events in each arm.

CONCLUSIONS: No DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis. Pulmonary artery occlusions developed only in the o.d. group. Our trial is underpowered and with few events.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:52

Enthalten in:

European journal of clinical investigation - 52(2022), 5 vom: 09. Mai, Seite e13735

Sprache:

Englisch

Beteiligte Personen:

Morici, Nuccia [VerfasserIn]
Podda, GianMarco [VerfasserIn]
Birocchi, Simone [VerfasserIn]
Bonacchini, Luca [VerfasserIn]
Merli, Marco [VerfasserIn]
Trezzi, Michele [VerfasserIn]
Massaini, Gianluca [VerfasserIn]
Agostinis, Marco [VerfasserIn]
Carioti, Giulia [VerfasserIn]
Saverio Serino, Francesco [VerfasserIn]
Gazzaniga, Gianluca [VerfasserIn]
Barberis, Daniela [VerfasserIn]
Antolini, Laura [VerfasserIn]
Grazia Valsecchi, Maria [VerfasserIn]
Cattaneo, Marco [VerfasserIn]

Links:

Volltext

Themen:

Anticoagulants
COVID-19
Enoxaparin
Journal Article
Multicenter Study
Pulmonary embolism
Randomized Controlled Trial
Thrombosis

Anmerkungen:

Date Completed 14.04.2022

Date Revised 14.04.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1111/eci.13735

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM334940060